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Background: Previously we assessed risk factors for FEV1 decline in children and adolescents using the Epidemiologic Study of Cystic Fibrosis
(J Pediatr 2007;151:134–139); the current study assessed risk factors in adults.
Methods: Risk factors for FEV1 decline over 3–5.5 years for ages 18–24 and ≥25 years were assessed using mixed-model regression.
Results:Mean rates of FEV1 decline (% predicted/year) were −1.92 for ages 18-24y (n=2793) and −1.45 for ages≥25y (n=1368). For the 18-24y
group, B. cepacia, pancreatic enzyme use, multidrug-resistant P. aeruginosa, cough, mucoid P. aeruginosa, and female sex predicted greater
decline; low baseline FEV1 and sinusitis predicted less decline. For the ≥25y group, only pancreatic enzyme use predicted greater decline; low
baseline FEV1 and sinusitis predicted less decline.
Conclusions: Risk factors for FEV1 decline in adults b25 years are similar to those previously identiﬁed in children and adolescents; older adults
had few statistically signiﬁcant risk factors.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Epidemiology; FEV1; Rate of decline; Risk factors1. Introduction
Loss of lung function as measured by forced expiratory
volume in 1 second (FEV1) in cystic fibrosis (CF) patients
varies between individuals and over time and is associated
with increased mortality [1,2]. In a previous report using
data from the Epidemiologic Study of Cystic Fibrosis
(ESCF), we evaluated risk factors for decline in FEV1 for
patients age 6–17 years [3]. We confirmed the findings of
other authors that an increased risk of lung function decline⁎ Corresponding author. Tel.: +1 216 844 3884; fax: +1 216 844 1479.
E-mail addresses: Michael.Konstan@UHhospitals.org,
michael.konstan@case.edu (M.W. Konstan).
1 For the Investigators and Coordinators of the Epidemiologic Study of Cystic
Fibrosis.
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.03.009is associated with high baseline lung function, female sex,
pancreatic insufficiency (as indicated by enzyme use), poor
nutritional status, and infection with Pseudomonas aerugi-
nosa. We also identified crackles, daily sputum production,
wheezing, sinusitis, the number of pulmonary exacerbations
treated with intravenous (IV) antibiotics, and elevated liver
function tests as additional risk factors for FEV1 decline in these
children. The magnitude and significance of the effect of these
risk factors on FEV1 decline (% predicted/year) varied depending
on the patient's age group (6–8, 9–12, or 13–17 years).
Previous studies of risk factors for lung function decline have
not focused specifically on adults with CF, or did not evaluate
adults separately by age groups, possibly due to small numbers of
patients available for analysis. ESCF includes information on a
large number of adult patients collected over more than 10 years,
allowing a comprehensive analysis of risk factors for decline inby Elsevier B.V. All rights reserved.
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characterize the decline in FEV1 % predicted over a 3–5.5-year
period in adults with CF; and (b) identify and compare risk factors
for decline in FEV1 % predicted in two adult age groups (18–24
and ≥25 years old) and to compare these risk factors with those
from children and adolescents from our previous work [3].
2. Methods
ESCF was a prospective, multicenter, encounter-based, obser-
vational study designed to characterize the natural history of CF in
a large population of patients in the US and Canada. Clinical,
therapeutic, microbiologic, and pulmonary function data were
collected from 1994 to 2005 [4]. The study was approved by the
Copernicus Group institutional review board (tracking num-
ber OVA1-03-008). Where required, it was approved by local
institutional review boards, and participants or their guardians
provided informed consent.
Patients 18 years old and above were included in this
analysis if they had at least 3 spirometries performed at times of
clinical stability: one at baseline (from the lead-in period), one
13–24 months after baseline, and one 49–78 months after
baseline (Fig. 1). Clinical characteristics and at least one
respiratory tract culture result were required during the 12-month
lead-in period following the baseline spirometry. The subsequent
66 months (5.5 years) comprised the outcome period during which
the rate of decline in FEV1% predicted was calculated. We
included only spirometry measures obtained at times of clinical
stability. For each 6 months of the outcome period, we included at
most one spirometry (the one closest to the midpoint) in order to
reduce potential bias due to frequency of testing. The equations of
Hankinson et al. [5] were used to calculate FEV1 % predicted.
Repeated-measures, mixed-model linear regression analysis was
used to estimate mean rate of change in FEV1% predicted within
age groups and to assess risk factors for decline in FEV1%
predicted.
Potential risk factors were derived from information obtained at
the baseline encounter, the last encounter during the lead-in period,
the last respiratory tract culture during lead-in, or from information
throughout the lead-in period. Potential risk factors from the
baseline encounter were sex, age at baseline spirometry, andBASELINE FEV1: 
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Fig. 1. Schematic obaseline FEV1% predicted (from the lead-in period). Nutritional
indices (height-for-age, weight-for-age, and body mass index)
were obtained from the last visit during the lead-in period. The last
respiratory tract culture result during the lead-in period was used
to determine presence of P. aeruginosa (any mucoid, any non-
mucoid, or any multidrug-resistant), Staphylococcus aureus (any
MRSA, any MSSA), Haemophilus influenzae, Burkholderia
cepacia, Stenotrophomonas maltophilia, other gram-negative
organisms, atypical mycobacteria, Candida, and Aspergillus.
For other potential risk factors, which were assessed at
encounters throughout the 12-month lead-in period, patients
were categorized as positive for each characteristic that was
recorded on at least half of their encounters: signs and
symptoms included daily cough, daily sputum production,
clubbing, crackles, and wheezing; medical conditions includ-
ed hemoptysis, asthma, allergic bronchopulmonary aspergil-
losis (ABPA), sinusitis, nasal polyps, elevated liver function
tests, CF-related diabetes mellitus (using treatment with
insulin or an oral hypoglycemic agent as an indicator), and
pancreatic insufficiency (using treatment with pancreatic
enzymes as an indicator). An additional risk factor assessed
was the number of pulmonary exacerbations treated with IV
antibiotics (IV exacerbations) initiated during the 12-month lead-
in period. Other than these treatments used as indicators of
underlying medical conditions, we did not include therapies as
potential risk factors.
Risk factors were first assessed one at a time for their overall
effect on the rate of decline separately by age group using linear
regression. Risk factors with pb .10 were then entered into
multivariable linear regression models with backwards selec-
tion, separately by age group, retaining those with pb .05. Risk
factors retained in either age group were combined in the final
multivariable model for both age groups. Final estimated rates
of decline and 95% confidence intervals were generated using
the ESTIMATE statement within the MIXED procedure in
SAS Version 9.1 (SAS Institute, Inc., Cary, NC).
3. Results
From the 32,585 patients enrolled in ESCF between 1994
and 2005, 14,283 had a stable baseline spirometry after the 18thDiscontinue
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Fig. 3. Estimated decline in FEV1% predicted by age group. Vectors representing
the observed average changes in FEV1 % predicted over the study period for the
two adult age groups in this study are plotted together with 3 vectors previously
published for younger patients with CF. For each age group, the line segment
is positioned to begin at the mean age at study baseline and extends to cover
the central 90% of follow-up (approximately 5 years). For example, the line for the
age≥25y group is centered at about age 35 and extends about 5 years, but represents
the average decline over a 5-year period across all ages 25 and older.
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application of the additional inclusion criteria (initial outcome
spirometry, a qualifying outcome spirometry, and evaluable
baseline encounter and microbiology data), a total of 4161
patients (2793 ages 18–24; 1368 ages 25 and older) met the
study inclusion criteria, as shown in Fig. 2. The patient
distribution of the time between baseline and initial outcome
spirometries was as follows: 13–15 months (58%), 16–18 months
(25%), 19–21 months (11%), and 22–24 months (7%). For the
time between baseline and qualifying outcome spirometries, the
patient distribution was as follows: 49–54 months (14%),
55–60 months (12%), 61–66 months (11%), 67–72 months
(17%), and 73–78 months (47%).
The mean duration of observation during the outcome period
(from the end of the lead-in year to the last spirometry) was
4.6 years (SD=0.8). The median number of spirometries included
per patient was 8. The mean rates of FEV1 decline for the 18-24y
and≥25y groups over the observation period were−1.92 (95%CI
−2.04 to −1.81) and −1.45 (95% CI −1.62 to −1.27) % predicted
per year, respectively. Fig. 3 shows these results for the two groups
of adults in this study in the context of the previously reported
results for children and adolescents [3].
We considered 30 risk factors for inclusion in the multivar-
iable model. Half of these variables were found not to have a
univariate relation significant at pb .10 with change in FEV1 and
were therefore eliminated from consideration for subsequent
multivariable modeling (Table 1, dark shading). Of the remaining
15 variables, all of which were significant by univariate analysis,
7 failed to be statistically significant at pb .05 in the multivariable
models for both age groups, and were excluded from the final
multivariable regression model (Table 1, light shading). The final
set of 8 risk factors are those that were significant in either age
group (Table 1, not shaded). The two final multivariable models
are shown in Table 2, and the independent effect and estimated
rate of decline are shown in Fig. 4. To determine the rate of FEV1Ages > 25Ages 18-24
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Fig. 2. Patient disposition.change predicted by this model for an individual patient with CF
using Fig. 4, the independent risk factors are added to the overall
rate of decline (first row). For example, the estimated annual rate
of FEV1 change over the next 4 years for a 20-year-old female
with 60% predicted FEV1 who coughs daily, does not have
sinusitis, is taking pancreatic enzymes, has mucoid P. aeruginosa
that is multidrug-resistant, but does not have B. cepacia is −1.92
(overall mean) −0.13 (female)−0.25 (FEV1 40%-69% predicted)
−0.08 (daily cough) −0.05 (no sinusitis) −0.08 (pancreatic
enzyme use) −0.15 (positive for mucoid P. aeruginosa) −0.57
(positive for multidrug-resistant P. aeruginosa) +0.04 (negative
for B. cepacia)=−3.19 percent predicted points of expected
FEV1 per year. In other words, this patient's FEV1 percent
predicted would be expected to drop by 13 percentage points
(from 60% predicted to 47% predicted) during the next four
years. In contrast, a patient with the same characteristics except
being age ≥25 years would have an estimated rate of decline of
−1.82, leading to a 4-year predicted drop of only 7 percentage
points.
The impact of multidrug-resistant P. aeruginosa on observed
rates of decline was substantial in the younger adults, where the
observed rate of decline was −2.49 percentage points per year
for those with multidrug-resistant P. aeruginosa compared with
−1.88 percentage points per year for those without. For older
adults, multidrug-resistant P. aeruginosa did not affect decline
estimates. B. cepacia also had a greater negative effect on the
estimated decline for the younger compared with the older
adults. Younger pancreatic-sufficient adults (based on pancre-
atic enzyme use) had a smaller rate of decline than pancreatic-
insufficient patients within the same age group, a difference that
was less pronounced for older adults. A comparison of baseline
FEV1 categories in the multivariable models shows that patients
in the lowest baseline FEV1 category (b40% predicted) declined
less rapidly than those with higher FEV1 in both age groups,
Table 2
Statistical significance of factors in final multivariable models, by age group.
p value
Factor Age 18-24y
n=2793
Ages≥25y
n=1368
Female .028 .332
Baseline FEV1 % predicted b.001 b.001
Daily cough .008 .411
Sinusitis .025 .049
Pancreatic enzyme use b.001 .037
Mucoid P. aeruginosa .007 .489
Multidrug-resistant P. aeruginosa .010 .929
B. cepacia .002 .199
Table 1
Patient characteristics by age group.
Characteristic Ages 18-24y
Association 
with decline
(p value*)
Ages≥25y 
Association 
with decline
(p value*)
Total patients, N N =  2793 N = 1368
Sex, n (%) 
Male 1469 (52.6%) .028 733 (53.6%) .368
Female 1324 (47.4%) 635 (46.4%)
Baseline FEV1 % predicted, n (%) 
100+ 204 (7.3%) <.001 26 (1.9%) <.001
70–<100 1080 (38.7%) 327 (23.9%)
40–<70 1176 (42.1%) 662 (48.4%)
<40 333 (11.9%) 353 (25.8%)
Daily cough, n (%) 2146 (76.8%) .011 1134 (83.0%) .512
Sinusitis, n (%) 253 (9.1%) .063 187 (13.7%) .053
Pancreatic enzyme use, n (%) 2617 (93.7%) <.001 1147 (84.0%) .088
Mucoid P. aeruginosa, n (%) 1466 (52.5%) .013 701 (51.2%) .703
Multidrug -resistant P. aeruginosa, n (%) 167 (6.0%) .004 98 (7.2%) .754
B. cepacia, n (%) 125 (4.5%) .010 50 (3.7%) .185
Daily sputum, n (%) 1749 (62.6%) .015 1022 (74.8%) .548
Clubbing, n (%) 2094 (75.0%) .007 1035 (75.8%) .680
Wheezing, n (%) 175 (6.3%) .056 196 (14.3%) .249
Asthma, n (%) 474 (17.0%) .053 271 (19.8%) .216
Number of IV exacerbations, n (%) 
0 1436 (51.4%) .052 783 (57.2%) .725
1 697 (25.0%) 339 (24.8%)
2 323 (11.6%) 160 (11.7%)
3 183 (6.6%) 51 (3.7%)
4+ 154 (5.5%) 35 (2.6%)
Other gram-negative bacteria, n (%) 305 (10.9%) .173 177 (12.9%) .146
Aspergillus, n (%) 207 (7.4%) .192 153 (11.2%) .060
Weight-for-age z score, Mean ± SD −0.9 ± 1.16 .532 −0.5 ± 1.15 .579
Height-for-age z score, Mean ± SD −0.5 ± 1.04 .134 −0.4 ± 1.03 .948
BMI z score, mean ± SD −0.8 ± 1.12 .893 –0.4 ± 1.13 .569
Crackles, n (%) 999 (35.8%) .685 667 (48.8%) .221
Hemoptysis, n (%) 34 (1.2%) .572 35 (2.6%) .917
ABPA, n (%) 85 (3.0%) .618 22 (1.6%) .214
Nasal polyps, n (%) 216 (7.7%) .664 91 (6.7%) .911
Elevated liver enzymes, n (%) 83 (3.0%) .403 33 (2.4%) .212
Nonmucoid P. aeruginosa, n (%) 1419 (50.8%) .435 649 (47.4%) .391
MSSA, n (%) 1009 (36.1%) .439 398 (29.1%) .331
MRSA, n (%) 44 (1.6% ) .733 10 (0.7%) .797
H. influenzae, n (%) 204 (7.3%) .862 92 (6.7%) .759
S. maltophilia, n (%) 69 (2.5%) .842 54 (3.9%) .541
Candida, n (%) 267 (9.6%) .773 135 (9.9%) .310
Insulin or oral hypoglycemic, n (%) 301 (10.8%) .118 187 (13.7%) .703
*p values evaluate the univariate association between each variable and
decline in FEV1% predicted.
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part to a survivor effect arising because patients had to remain
alive for a minimum of 3 years after the baseline to be included
in this analysis. Patients with particularly low lung function who
died or had a lung transplant before the minimum follow-up
time are excluded from this prediction.
To better evaluate the impact of risk factors on rates of
decline in older adults, as well as any influence patients with
low FEV1 had on the overall model, two additional analyses
were performed. First, we refit the model separately for patients
age 25-31y (n=772) and ≥32y (n=606) and found no material
differences between these two age groups with respect to
impact of risk factors on rates of decline. Second, we repeated
the modeling process, beginning with the backward stepwise
regression, after excluding all patients with FEV1b40%
predicted. In this subset analysis, we found baseline FEV1 %
predicted and daily cough were no longer significant risk
factors for the 18–24 year old patients, whereas daily sputum
(p=.031) and asthma (p=.028) became significant negative
factors. In the ≥25-year age group with FEV1 ≥40%
predicted, the risk factors changed only slightly with two
exceptions: the magnitude of the effect of pancreatic enzyme
use was similar, but was no longer statistically significant, and
Aspergillus became a significant negative risk factor (p=.043)
4. Discussion
This study used data from ESCF, a large, prospective
observational study of patients with CF [4]. We characterized
the rate of FEV1 decline in adults for two age groups: 18-24y
and ≥25y. The overall values and average rates of decline of
FEV1 % predicted that we found for the younger adults (Fig. 3)
were remarkably consistent with those we previously reported
for children and adolescents [3]. FEV1 % predicted values and
rates of decline among adults ≥25y were better than might be
expected based upon the results of the younger patients (Fig. 3).
This finding presumably reflects a survivor effect as evidenced
by genotype and pancreatic function differences reported in
older CF patients [6,7].
The impact of risk factors for decline in FEV1 % predicted in
adults with CF was assessed using multivariable regression.
Many variables that were identified as significant independent
risk factors for lung function decline in younger CF adults
(18-24y) were similar to those observed for children and
adolescents ages 6-17y with CF in our previous study [3]. Low
FEV1 (b40% predicted) and presence of sinusitis were associated
with a lower rate of decline. Being female, having daily cough,
using pancreatic enzymes, and having a positive culture for B.
cepacia or for mucoid or multidrug-resistant P. aeruginosa were
all associated with greater rate of decline.
For the older adults (≥25y), baseline FEV1 was the only
strong predictor of lung function decline, again with low FEV1
(b40% predicted) being associated with a lower rate of decline.
In these older adults, the estimated effects of the risk factors
were similar to young adults, but tended to be somewhat smaller
in magnitude and have wider confidence bounds, partially due
to the smaller number of older patients. The P. aeruginosa
Fig. 4. Results of multivariable models of FEV1 percent predicted by age group. Risk factors remaining in the final multivariable regression (Table 2) are shown in the
left column. For a patient in either the 18–24y group (left) or ≥25y group (right), an estimate of the rate of annual decline in FEV1 percent predicted is obtained by
summing parameter estimates (labeled “Est.”) associated with each variable state for the patient. The graphical display shows the reference line (mean rate of decline
for each age group), the estimated effect of each variable, and the associated 95% confidence interval.
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resistant P. aeruginosa appeared to have an impact on rate
of lung function decline in older adults with CF. Marginal
statistical significance was reached for pancreatic enzyme use
(a surrogate for pancreatic insufficiency) and sinusitis. Risk
factors may have fallen short of statistical significance in the
older age group not only because of smaller numbers, but also
because risk factors present for many years might no longer be
changing the course of the patients’ lung disease.
Patients with low FEV1 (b40% predicted) tend to have only
modest decline compared to those with higher lung function.
This phenomenon has been previously described and is partly
due to a “floor” effect [8–10]. To better understand the risk
factors for decline in lung function in adults without the
influence of these patients, we repeated the analyses including
only patients with FEV1≥40% predicted. For the younger
adults, we found that daily cough was no longer a risk factor;
however, daily sputum production and asthma became signif-
icantly associated with lung function decline. Further, in this
healthier subgroup, baseline FEV1 % predicted was no longer arisk factor in either age group. This finding differs from our
previously reported results in children and adolescents, where
patients with higher baseline lung function had a greater risk
for more rapid decline [3]. In that paper, we speculated that
children with the highest lung function were not treated
aggressively. Among the adults with baseline FEV1≥40%
predicted, only 8% of young adults and 3% of older adults had
FEV1 ≥100% predicted, and it is for this group that treatment
may be least aggressive. This concentration of the values of
FEV1 % predicted into a narrow range may explain why
baseline level of lung function was not predictive of subsequent
decline in this subset.
Interestingly, the presence of sinusitis, which often corre-
lates with increased lower respiratory symptoms [11], was
associated with a lower decline in FEV1 in both age groups and
regardless of whether patients with FEV1 less than 40%
predicted were excluded. In ESCF, the medical condition of
sinusitis was recorded only for currently symptomatic sinusitis,
which was likely treated. We conjecture that antibiotic therapy
for sinusitis may have incidentally treated lung disease and
410 M.W. Konstan et al. / Journal of Cystic Fibrosis 11 (2012) 405–411thereby slowed the decline in FEV1. It is also possible that
patients with severe sinusitis were treated surgically and are no
longer symptomatic, leaving only patients with mild sinusitis.
Our findings confirm earlier reports that higher FEV1,
airway infection with P. aeruginosa, female sex, and poorer
nutritional status are among those factors associated with
higher rates of FEV1 decline in children and/or adults with CF
[1,8,12–16]. It is noteworthy that the well-established gender
differences in childhood and adolescence are still significant in
adulthood. In this study, we not only focused exclusively upon
adults, but also divided the adult population into those above
and below 25 years of age. Our study also includes a large
selection of potential risk factors, a number of which were not
found to be significant in this analysis. For some factors, this
may be because they are relatively rare (e.g., hemoptysis and
ABPA). For other factors, this may be because adult patients
typically have had the risk factor for an extended period, and
thus the disease progression associated with its onset has
already occurred (e.g., crackles). We were unable to adequately
assess genotype and socioeconomic status information on
enough patients to warrant including those factors in the
analysis.
Adult CF patients commonly have fairly frequent respiratory
exacerbations which are treated with IV antibiotics. The frequency
of these exacerbations has been associated with an increased risk
for lung transplantation or death [17]. However, in contrast to our
previous finding in children and adolescents, the number of IV
exacerbations during the baseline year was not a statistically
significant predictor of change in FEV1 in adults after controlling
for other risk factors, even when limited to patients with FEV1
≥40% predicted. This could be related to survivor effect, more
aggressive treatment of exacerbations in adults, or differences in
the pathophysiology and progression of lung disease in adults.
Further, the decision to treat an exacerbation in adults may be
conditioned upon a patient's wishes or social concerns more than
for younger patients. This would tend to weaken any relationship
between exacerbation frequency and subsequent lung function
decline.
This analysis provides insight into risk factors for FEV1
decline in adults and identifies a marked age effect for different
risk factors. The effect of baseline FEV1 was quite striking
when considering all adults and reinforces our previous finding
in children and adolescents that low FEV1 predicts a smaller
decline in FEV1 % predicted. Lung disease progression is not
uniform within the adult CF population. It is possible that
modeling relative change in FEV1 % predicted rather than
absolute change would better reflect the natural course of CF
lung function and might even eliminate the protective effect
associated with FEV1b40% predicted. Identification of specific
patient characteristics (i.e., risk factors) associated with more
rapid disease progression can not only better inform patient
management, but can also aid in the design and analysis of
clinical trials to assess new CF therapies targeted at arresting
lung disease progression [18]. Similar to our previous study on
children and adolescents [3], we also provide clinicians with a
method for estimating the rate of FEV1 decline in an individual
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